Molecular prognostic and predictive factors in sarcomas

Margaret P. Holmes, Kamyar Khazaeian, Saba Agegnehu, I. Tien Yeh

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The use of molecular markers in sarcomas has been primarily for diagnosis, but increasingly they are also used for prognosis and prediction of response to specific therapies. This article presents 3 case reports of sarcomas to illustrate molecular markers for prognosis/predictive purposes. The prototypical example is gastrointestinal stromal tumor, in which the response to imatinib mesylate therapy is predicted by analysis for KIT mutation. In synovial sarcomas, the type of fusion transcript correlates with the clinical course, with SST-SSX2 having better metastasis-free survival than SYT-SSX1. p53 Mutation is an important prognostic factor in multiple tumors, including Ewing sarcoma. Many studies are ongoing, and molecular analysis will become increasingly important in the treatment of sarcomas.

Original languageEnglish (US)
Pages (from-to)269-275
Number of pages7
JournalPathology Case Reviews
Issue number5
StatePublished - Dec 10 2014
Externally publishedYes


  • Ewing sarcoma
  • Gastrointestinal stromal tumor
  • Prognosis
  • Sarcoma
  • Synovial sarcoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Molecular prognostic and predictive factors in sarcomas'. Together they form a unique fingerprint.

Cite this